AI assistant
PFIZER INC — Director's Dealing 2022
Mar 1, 2022
29831_dirs_2022-03-01_bd4e7c48-f405-4aa3-bc80-25123ee67f97.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2022-02-26
Reporting Person: LANKLER DOUGLAS M (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-26 | Common Stock | M | 77709.0000 | $25.6000 | Acquired | 174507.0000 | Direct |
| 2022-02-26 | Common Stock | F | 21149.0000 | $47.7200 | Disposed | 153358.0000 | Direct |
| 2022-02-26 | Common Stock | F | 36282.0000 | $50.6400 | Disposed | 117076.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-26 | Stock Appreciation Rights | $25.6000 | M | 77709.0000 | Disposed | 2022-02-26 | Common Stock (77709.0000) | Direct |
| 2022-02-28 | Stock Appreciation Rights | $46.9400 | A | 10566.0000 | Acquired | 2027-02-28 | Common Stock (10566.0000) | Direct |
| 2022-02-28 | Stock Appreciation Rights | $46.9400 | A | 9294.0000 | Acquired | 2029-02-28 | Common Stock (9294.0000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1681.0000 | Indirect |
Footnotes
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3: Price is the closing price of Pfizer common stock on February 25, 2022.
F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
F6: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
F7: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.